Green light from NICE for Stivarga in GIST

12 October 2017

The UK’s National Institute for Health and Clinical Excellence (NICE) has today given a positive recommendation for Stivarga (regorafenib) for use for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.

Regorafenib, from German pharma major Bayer (BAYN: DE), has been available for patients with GIST on the Cancer Drugs Fund since 2013. This decision by NICE, the cost-effectiveness watchdog for England and Wales, will mean physicians and those patients with unresectable or metastatic GIST who failed or are intolerant to previous therapies will now have routine access to regorafenib.

Stivarga generated sales of 83 million euros ($97 million) in the second quarter of this year, a year-on-year rise of 24%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK